EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 148 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $221 | +317.0% | 42,039 | +1443.8% | 0.00% | – |
Q2 2023 | $53 | -31.2% | 2,723 | 0.0% | 0.00% | – |
Q1 2023 | $77 | -3.8% | 2,723 | 0.0% | 0.00% | – |
Q4 2022 | $80 | -99.9% | 2,723 | 0.0% | 0.00% | – |
Q3 2022 | $72,000 | -40.5% | 2,723 | 0.0% | 0.00% | -100.0% |
Q2 2022 | $121,000 | -10.4% | 2,723 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $135,000 | -2.9% | 2,723 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $139,000 | -8.6% | 2,723 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $152,000 | +29.9% | 2,723 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $117,000 | +2.6% | 2,723 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $114,000 | -10.2% | 2,723 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $127,000 | +9.5% | 2,723 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $116,000 | -11.5% | 2,723 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $131,000 | +4.8% | 2,723 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $125,000 | -23.8% | 2,723 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $164,000 | +6.5% | 2,723 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $154,000 | +1.3% | 2,723 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $152,000 | +10.9% | 2,723 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $137,000 | +24.5% | 2,723 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $110,000 | -41.8% | 2,723 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $189,000 | -8.3% | 2,723 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $206,000 | +44.1% | 2,723 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $143,000 | -1.4% | 2,723 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $145,000 | -10.5% | 2,723 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $162,000 | -24.7% | 2,723 | 0.0% | 0.00% | -50.0% |
Q2 2017 | $215,000 | -4.9% | 2,723 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $226,000 | -1.7% | 2,723 | -6.2% | 0.00% | 0.0% |
Q4 2016 | $230,000 | +12.2% | 2,902 | -0.8% | 0.00% | 0.0% |
Q3 2016 | $205,000 | +81.4% | 2,926 | 0.0% | 0.00% | +100.0% |
Q2 2016 | $113,000 | -5.0% | 2,926 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $119,000 | -38.7% | 2,926 | +33.9% | 0.00% | -50.0% |
Q4 2015 | $194,000 | +19.8% | 2,185 | 0.0% | 0.00% | +100.0% |
Q3 2015 | $162,000 | -8.5% | 2,185 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $177,000 | – | 2,185 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |